Transplant Patients Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Transplant Patients clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Personalized Immunological Score for the Prediction of Severe Infectious Events in Immunocompromised Patients and Tailored Management (PERISCOPE)

InfectionsImmunocompromised PatientsTransplant Patients
Fondazione IRCCS Policlinico San Matteo di Pavia150 enrolled1 locationNCT07379554
Recruiting
Phase 2

Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Chinese PLA General Hospital100 enrolled1 locationNCT06393361
Recruiting
Phase 1Phase 2

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

E Coli InfectionsAllogenic Transplant Patients
SNIPR Biome Aps.24 enrolled8 locationsNCT06938867
Recruiting
Not Applicable

Search for Noninvasive Markers of "Graft Injury" in Pediatric and Adult Patients With Congenital Heart Disease Undergoing Cardiac Transplantation

Adult Congenital Heart DiseaseCongenital Heart Disease (CHD)Heart Transplant Patients+1 more
IRCCS Azienda Ospedaliero-Universitaria di Bologna20 enrolled1 locationNCT06784440
Recruiting

Observational Single-center Study of the Relationship Between Arterial Hypertension and Hypervolemia Defined by Self-measurement of Impedancemetry in Kidney Transplant Patients With Transplantation Less Than 6 Months Old

Kidney Transplant Patients
Nantes University Hospital150 enrolled1 locationNCT05039788
Recruiting

High-flow nasal oxygenation in sedated lung transplant patients during transbronchial biopsy

Oxygenation during transbronchial biopsyLung transplant patients
Dr Charles Cartwright80 enrolled1 locationACTRN12619000292178
Recruiting
Phase 2

Phase 2 Randomised controlled trial of bone-marrow derived mesenchymal stromal cells (MSC) for new onset chronic lung allograft dysfunction (CLAD)

Lung transplant patients with Chronic Lung Allograph Dysfunction (CLAD)
University of Queensland82 enrolled5 locationsACTRN12616000338460